Anthony T. Reder to Magnetic Resonance Imaging
This is a "connection" page, showing publications Anthony T. Reder has written about Magnetic Resonance Imaging.
Connection Strength
0.594
-
Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy. Immunotherapy. 2021 01; 13(1):11-17.
Score: 0.081
-
Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS. Mult Scler. 2021 06; 27(7):1008-1013.
Score: 0.080
-
Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon ß-1a in the EVIDENCE study. J Neurol Sci. 2017 Aug 15; 379:151-156.
Score: 0.065
-
The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013 Nov; 19(13):1765-72.
Score: 0.049
-
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 08; 74(23):1877-85.
Score: 0.040
-
Multiple sclerosis. Part I: neuro-ophthalmic manifestations. Curr Opin Ophthalmol. 2009 Nov; 20(6):467-75.
Score: 0.038
-
4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology. 2009 Mar 24; 72(12):1100-1.
Score: 0.037
-
Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
Score: 0.035
-
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008 Oct 28; 71(18):1390-5.
Score: 0.035
-
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
Score: 0.024
-
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Mult Scler. 2022 04; 28(5):790-800.
Score: 0.022
-
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
Score: 0.018
-
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2019 05; 25(6):837-847.
Score: 0.017
-
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56.
Score: 0.013
-
Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica. J Neuroophthalmol. 2012 Jun; 32(2):150-3.
Score: 0.011
-
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ß-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-7.
Score: 0.011
-
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug; 81(8):907-12.
Score: 0.010
-
Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996 Dec; 47(6):1463-8.
Score: 0.004
-
Three-dimensional human pattern visual evoked potentials. II. Multiple sclerosis patients. Electroencephalogr Clin Neurophysiol. 1991 Sep-Oct; 80(5):339-46.
Score: 0.003
-
Internal capsule plaque and tonic spasms in multiple sclerosis. Arch Neurol. 1991 Apr; 48(4):427-9.
Score: 0.003